Clinical Report: Tailoring Aciclovir Dosage in Obese Pediatric Patients

Background

The rise in childhood obesity complicates safe medication prescribing, particularly for aciclovir, where conventional dosing guidelines may lead to underdosing or toxicity. Pharmacovigilance data indicate a significant number of adverse reactions in pediatric patients. Current guidelines do not adequately address the unique pharmacokinetic considerations in obese children.

Data Highlights

No numerical data available in the source material.

Key Findings

• Conventional weight-based and BSA-based dosing guidelines for aciclovir may not be suitable for obese pediatric patients.
• Pharmacovigilance data show over 100 adverse reaction reports related to aciclovir in children since 2015.
• Using ideal body weight (IBW) for children above the 98th percentile may lead to inappropriate dose reductions.
• Adjusted body weight (AdjBW) offers a more accurate dosing alternative, particularly for children above the 50th weight centile.
• A blended dosing approach can mitigate abrupt transitions in dosing regimens at age 12.

Clinical Implications

Clinicians should consider using AdjBW in BSA calculations for aciclovir dosing in obese pediatric patients to enhance safety and efficacy. The proposed blended dosing strategy may provide a more consistent approach to prescribing across age transitions.

Conclusion

The analysis highlights the need for more nuanced dosing strategies for aciclovir in pediatric patients with obesity.

Related Resources & Content

1. ASCO Post, ASCO Issues New Guideline on Chemotherapy Dosing for Obese Patients, 2012 -- ASCO Issues New Guideline on Chemotherapy Dosing for Obese Patients
2. Open Forum Infectious Diseases, Comparative Analysis of Acute Kidney Injury Incidence Between Area Under the Concentration–Time Curve and Trough-Based Vancomycin Dosing in Obese Patients, 2023 -- Comparative Analysis of Acute Kidney Injury Incidence Between Area Under the Concentration–Time Curve and Trough-Based Vancomycin Dosing in Obese Patients
3. Herpes Simplex Virus: Adult and Adolescent OIs | NIH -- Herpes Simplex Virus: Adult and Adolescent OIs
4. The ASCO Post — ASCO Issues New Guideline on Chemotherapy Dosing for Obese Patients
5. Bone Marrow Transplantation — Timing Considerations for High-Dose Chemotherapy in Overweight and Obese Individuals
6. Gaps in Drug Dosing for Obese Children: A Systematic Review of Commonly Prescribed Acute Care Medications
7. Safety of Different Weight-Based Dosing Strategies of Intravenous Acyclovir in Obese Patients: A Retrospective Cohort Study
8. Herpes Simplex Virus: Adult and Adolescent OIs | NIH